LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTC: IMUC) (IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has appointed three new members, Colonel George Peoples, M.D. Director of the Cancer Vaccine Development Program and Deputy Director of the United States Military Cancer Institute (USMCI), Dr. Constantine Ioannides, Professor of Immunology at the M.D. Anderson Cancer Center, and Dr. Cohava Gelber, Chief Scientific & Technology Officer of ATCC to its Scientific Advisory Board. The recommendations were made with the strong support of the Company’s Board of Directors, who cited these individuals’ impressive research credentials and leadership within the field of immunotherapeutics and monoclonal antibodies for cancer research.
